Ucbbiopharma Srl

Ucb Pharma, S.a.

Celltech R&d Limited

Ucb Biopharma Sprl

Other

Timothy John Norman

John Robert Porter

Boris Kroeplien

Graham John Warrellow

Stephen Edward Rapecki

Alastair Lawson

James Philip O'Connell

Terence Seward Baker

Rikki Peter Alexander

John Clifford Head

Mark Daniel Calmiano

Andrew James Ratcliffe

William Ross Pitt

Giancarlo Trani

Michael Anthony William Eaton

Zhaoning Zhu

Daniel Christopher Brookings

Sarah Catherine Archibald

Barry John Langham

James Andrew Johnson

David Parker

Daniel John Lightwood

Matthew Duncan Selby

Fabien Claude Lecomte

Martin Alexander Lowe

Janeen Marsha Linsley

Brian Woodside Hutchinson

Tracy Lynn Arakaki

Oliver Philps

David Andreas Schubert

Alex Buntin Burgin

Andrew Neil Charles Weir

Catherine Fiona Catterall

Gregory William Haslett

Martin Clive Hutchings

Judi Charlotte Neuss

James Thomas Reuberson

Jag Paul Heer

Pui Leng Loke

Stephen Brand

David G Parker

Stuart Bailey

Helen Tracey Horsley

Richard Jeremy Franklin

David James McMillan

Joanna Rachel Quincey

Gareth Neil Brace

Michael Anthony Eaton

Alistair James Henry

Anne Marie Foley

Mezher Hussein Ali

Michael Alan Shaw

Christopher Francis Palmer

Rebecca Jayne Munro

James Madden

Gregory Foulkes

Ellen Olivia Gallimore

Pavandeep Singh Aujla

Muhammed Kamal Uddin

Catherine McKay

Prafulkumar Tulshibhai Chovatia

Severine Danielle Jones

Konstantinos Rampalakos

Pfrafulkumar Tulshibhai Chovatia

Rickki Lee Connelly

Selvaratnam Suganthan

Donald Smyth

James Petrie Turner

Rebecca Jayne Wootton

Benjamin Charles De Candole

Ajay Mandal

Yolanda Pérez-Fuertes

Zeshan Yousuf

James Philip O'CONNELL

David James Mcmillan

COMPLEXES BETWEEN CD40 AND COMPOUNDS COMPRISING BENZIMIDAZOLE MOIETIES

The present invention relates to tetrahydrobenzo-isoquinoline sulfonamides derivatives of formula (I), processes for preparing them, pharmaceutical compositions containing them and their use in treating disorders caused by IgE (such as allergic responses, non-allergic mast cell responses or certain autoimmune responses), and in particular disorders caused by the interaction of IgE with the FIERI receptor.

Tetrahydrobenzo-quinoline sulfonamides derivative compounds

Thiophene derivatives of formula (I) and a pharmaceutically acceptable salt thereof are provided. These compounds have utility for the treatment or prevention of disorders caused by IgE, such as allergy, type 1 hypersensitivity or familiar sinus inflammation.

Thiophene derivatives for the treatment of disorders caused by IgE

A new, stable trimeric TNF&#x3b1; structure is disclosed with distorted symmetry which can bind to the TNFR1 receptor to attenuate signalling therefrom, which can be used in the treatment and/or prevention of diseases associated with the soluble TNF&#x3b1;/TNFR1 interaction. Membrane-bound TNF&#x3b1; is not affected in its ability to signal through TNFR2, and thus the new structure of TNF&#x3b1; may be used in therapies which do not significantly raise the risk of infection or malignancy.

Method of identifying potential inhibitors of APO TNF&#x3b1; trimers

It has been demonstrated that certain compounds bind to TNF and stabilise a conformation of trimeric TNF that binds to the TNF receptor. Accordingly, these compounds can be used as modulators of TNF. A new assay for identifying compounds with this mechanism of action is also disclosed.

Method for identifying a modulator of the TNF&#x3b1; or CD40L interaction with their cognate receptors

The invention is in the field of TNF signalling. Compounds have been identified which are capable of modulating signalling of TNF trimers through receptors. Methods of identifying such compounds are therefore provided. The compounds themselves have utility in therapy.

Methods of identifying signaling modulators of the trimeric TNFa

Compounds of formula (I), wherein Ar is an aryl group optionally further substituted with one or more groups R; A is a lipophilic, hydrophobic moiety; Ris a phosphodiester, phosphotriester, thioether or amide group; X is an unsubstituted or substituted Cto Calkylene or alkenylene group, which is optionally interrupted by one or more &#x2014;NR&#x2014;, &#x2014;O&#x2014; or &#x2014;S&#x2014; linkages, Ris &#x2014;YC(R)(R)COR; and pharmaceutically acceptable salts or solvates thereof are useful as endosomolytic agents particularly for the delivery of nucleic acids useful in gene therapy. 

Endosomolytic agents for gene therapy

Treatment of autoimmune and inflammatory disorders with asymmetric TNF alpha trimers

TNF receptor signaling modulator assay

A series of substituted 3,4-dihydro-2H-.1,4-benzoxazin-3-one derivatives, and analogs thereof, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neuradegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. 

Substituted benzo[b][1,4]oxazines and pyrido[3,2-b][1,4]oxazines as modulators of tumor necrosis factor activity

A series of benzimidazole derivatives, being potent modulators of human TNF&#x3b1; activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

TNF -&#x3b1; modulating benzimidazoles

The present invention provides a process for producing a comb polymer comprising the steps of: a) providing: (i) (w+z) molar equivalents of a monomer; (ii) one molar equivalent of an initiator compound of formula (IX), wherein Brepresents a halogen, Brepresents H or a halogen, Yrepresents a group capable of attaching the residue of an antibody or fragment thereof or capable of being converted into such a group, L represents a linker group, y is 1, 2 or 3, w is at least 1 and z is 0 or greater; (iii) a catalyst capable of catalysing the polymerization of a plurality of the monomers to produce the comb polymer; and b) causing the catalyst to catalyse, in combination with the initiator, the polymerization of a plurality of the monomers (i) to produce the comb polymer. 

Comb polymers

The present invention provides a compound consisting essentially of the following elements: one or more reactive groups; and two or more cross-linked antibodies or fragments thereof; characterised in that the or each reactive group is suitable for attaching an effector molecule but does not react with any of the antibodies or fragments thereof.

Cross-linked antibodies

The present invention provides an albumin-binding compound essentially of the following elements: a spacer group, a water-soluble bridging group, a fatty acid chain and an acidic group characterised in that the acidic group is attached to the distal end of the fatty acid chain. The invention also provides an albumin-binding compound to which one or more biologically active moieties are attached.

Albumin-binding conjugates comprising a fatty acid and PEG

Branched molecular scaffolds are provided which are capable of linking two polymer residues (derived, for example, from polyethylene glycol) to two, three or four residues derived from biologically active molecules (e.g. from whole antibodies or from functionally active fragments or derivatives thereof), the latter being attached to the scaffold by means of hydrolytically stable linkages.

Branched molecular scaffolds for linking polymer residues to biologically active moieties

Growing community of inventors

Slough, United Kingdom

Timothy John Norman